Vertex Pharmaceuticals and Sun Pharmaceutical Industries side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Vertex Pharmaceuticals | Sun Pharmaceutical Industries |
|---|---|---|
| Phase 1 | Vertex Pharmaceuticals: 4 of its 18 programs at phase 1 | Sun Pharmaceutical Industries: 10 of its 14 programs at phase 1
and 5 more — sign in to see them all |
| Phase 2 | Vertex Pharmaceuticals: 4 of its 18 programs at phase 2
| Sun Pharmaceutical Industries: 1 of its 14 programs at phase 2
|
| Phase 3 | Vertex Pharmaceuticals: 8 of its 18 programs at phase 3
and 3 more — sign in to see them all | Sun Pharmaceutical Industries: 2 of its 14 programs at phase 3 |
| Approved, new studies | Vertex Pharmaceuticals: 2 of its 18 programs at approved, new studies
| Sun Pharmaceutical Industries: 1 of its 14 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals12 readouts · 5 phase 3 | · | Vertex Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion
| Vertex Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Vertex Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion
| Vertex Pharmaceuticals, Mar ’27: 2 programs whose next study reaches primary completion
| Vertex Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Vertex Pharmaceuticals, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Vertex Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion
| Vertex Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion
| Vertex Pharmaceuticals, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | · |
| Sun Pharmaceutical Industries4 readouts · 2 phase 3 | · | Sun Pharmaceutical Industries, Dec ’26: 1 program whose next study reaches primary completion
| Sun Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3 | · | · | Sun Pharmaceutical Industries, Apr ’27: 1 program whose next study reaches primary completion
| Sun Pharmaceutical Industries, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Vertex Pharmaceuticals
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 4
- povetaciceptphase 3 · Dec 2028 → Jun 2029 (+6 mo) · moved Nov 18 · NCT07204275
- ivacaftorphase 1 · Nov 2026 → Jul 2027 (+8 mo) · moved Oct 19 · NCT07283770
- tezacaftorphase 1 · Nov 2026 → Jul 2027 (+8 mo) · moved Oct 19 · NCT07283770
- VX-581phase 1 · Nov 2026 → Jul 2027 (+8 mo) · moved Oct 19 · NCT07283770
Sun Pharmaceutical Industries
New programs 1
- Phenobarbitalapproved, new study · first study · Oct 13 · Seizures
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Vertex Pharmaceuticals | Sun Pharmaceutical Industries |
|---|---|---|
| COVID-19both · compare here | Vertex Pharmaceuticals in COVID-19: 1 program
Their studies: Vertex Pharmaceuticals’ studies of COVID-19 in search | Sun Pharmaceutical Industries in COVID-19: 1 program
Their studies: Sun Pharmaceutical Industries’ studies of COVID-19 in search |
| Renal Insufficiencyboth · compare here | Vertex Pharmaceuticals in Renal Insufficiency: 1 program
Their studies: Vertex Pharmaceuticals’ studies of Renal Insufficiency in search | Sun Pharmaceutical Industries in Renal Insufficiency: 1 program
Their studies: Sun Pharmaceutical Industries’ studies of Renal Insufficiency in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.